Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model

Neoplasia

Volumn 12, Issue 10, 2010, Pages 837-847

  Sengupta, Sadhak ^a   Nandi, Suvobroto ^a   Hindi, Enal S ^a   Wainwright, Derek A ^a   Han, Yu ^a   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; FIBRONECTIN; FIBRONECTIN RECEPTOR; PROTEIN TYROSINE KINASE; SHORT HAIRPIN RNA; STAT3 PROTEIN; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE SILENCING; GLIOMA; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR GROWTH; WILD TYPE;

EID: 77957773443     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10662     Document Type: Article

References (50)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996.
2. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, and Sampson JH (2009). EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 19, 713-723.
3. Ksendzovsky A, Feinstein D, Zengou R, Sharp A, Polak P, Lichtor T, and Glick RP (2009). Investigation of immunosuppressive mechanisms in a mouse glioma model. J Neurooncol 93, 107-114.
4. + regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8, 234-243.
5. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, and Fuller GN (2008). Incidence and prognostic impact of FoxP3+regulatory T cells in human gliomas. Clin Cancer Res 14, 5166-5172.
6. Sugihara AQ, Rolle CE, and Lesniak MS (2009). Regulatory T cells actively infiltrate metastatic brain tumors. Int J Oncol 34, 1533-1540.
7. Pankov R and Yamada KM (2002). Fibronectin at a glance. J Cell Sci 115, 3861-3863.
8. Pytela R, Pierschbacher MD, and Ruoslahti E (1985). Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor. Cell 40, 191-198.
9. Rooprai HK, Vanmeter T, Panou C, Schnull S, Trillo-Pazos G, Davies D, and Pilkington GJ (1999). The role of integrin receptors in aspects of glioma invasion in vitro. Int J Dev Neurosci 17, 613-623.
10. Han S, Khuri FR, and Roman J (2006). Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/ S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66, 315-323.
11. Sherbet GV, Tindle ME, and Stidolph S (1982). Fibronectin in human astrocytomas grown in tissue culture. Anticancer Res 2, 251-254.
12. Ohnishi T, Hiraga S, Izumoto S, Matsumura H, Kanemura Y, Arita N, and Hayakawa T (1998). Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin Exp Metastasis 16, 729-741.
13. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N, Tarin D, Shattil SJ, and Cheresh DA (2009). An integrin α(v)β(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15, 1163-1169.
14. Putnam AJ, Schulz VV, Freiter EM, Bill HM, and Miranti CK (2009). Src, PKCα, and PKCδ are required for αvβ3 integrin-mediated metastatic melanoma invasion. Cell Commun Signal 7, 10.
15. Yu CL, Meyer DJ, Campbell GS, Larner AC, Carter-Su C, Schwartz J, and Jove R (1995). Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83.
16. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, and Yu H (2002). Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 21, 7001-7010.
17. Brantley EC and Benveniste EN (2008). Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 6, 675-684.
18. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, et al. (2008). The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14, 8228-8235.
19. Dasgupta A, Raychaudhuri B, Haqqi T, Prayson R, Van Meir EG, Vogelbaum M, and Haque SJ (2009). Stat3 activation is required for the growth of U87 cell-derived tumours in mice. Eur J Cancer 45, 677-684.
20. Livak KJ and Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408.
21. Wang Y and Chien S (2007). Analysis of integrin signaling by fluorescence resonance energy transfer. Methods Enzymol 426, 177-201.
22. Cao X, Tay A, Guy GR, and Tan YH (1996). Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol 16, 1595-1603.
23. Bhattacharya S, Ray RM, and Johnson LR (2005). STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 392, 335-344.
24. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, and Darnell JE Jr (1999). Stat3 as an oncogene. Cell 98, 295-303.
25. Bromberg J and Darnell JE Jr (2000). The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473.
26. Costantino L and Barlocco D (2008). STAT 3 as a target for cancer drug discovery. Curr Med Chem 15, 834-843.
27. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, and Haque SJ (2002). Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 21, 8404-8413.
28. Thomas CY, Chouinard M, Cox M, Parsons S, Stallings-Mann M, Garcia R, Jove R, and Wharen R (2003). Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. Int J Cancer 104, 19-27.
29. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al. (2007). A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26, 2435-2444.
30. Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, Roarty K, and Benveniste EN (2008). Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res 14, 4694-4704.
31. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, and Heimberger AB (2007). A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67, 9630-9636.
32. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M, Akahane K, and Shiraki K (2000). Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 19, 3225-3234.
33. Zhen HN, Li LW, Zhang W, Fei Z, Shi CH, Yang TT, Bai WT, and Zhang X (2007). Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol 31, 1111-1117.
34. Mellai M, Caldera V, Patrucco A, Annovazzi L, and Schiffer D (2008). Survivin expression in glioblastomas correlates with proliferation, but not with apoptosis. Anticancer Res 28, 109-118.
35. Zhen HN, Zhang X, Hu PZ, Yang TT, Fei Z, Zhang JN, Fu LA, He XS, Ma FC, and Wang XL (2005). Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer 104, 2775-2783.
36. Cai L, Zhang G, Tong X, You Q, An Y, Wang Y, Guo L, Wang T, Zhu D, and Zheng J (2010). Growth inhibition of human ovarian cancer cells by blocking STAT3 activation with small interfering RNA. Eur J Obstet Gynecol Reprod Biol 148, 73-80.
37. Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, and London CA (2009). Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 9, 81.
38. Ritchie CK, Giordano A, and Khalili K (2000). Integrin involvement in glioblastoma multiforme: possible regulation by NF-κB. J Cell Physiol 184, 214-221.
39. Ulrich TA, de Juan Pardo EM, and Kumar S (2009). The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 69, 4167-4174.
40. Preto A, Goncalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, et al. (2009). Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer 9, 387.
41. Jung KM, Bae IH, Kim BH, Kim WK, Chung JH, Park YH, and Lim KM (2010). Comparison of flow cytometry and immunohistochemistry in non-radioisotopic murine lymph node assay using bromodeoxyuridine. Toxicol Lett 192, 229-237.
42. Hayman EG and Ruoslahti E (1979). Distribution of fetal bovine serum fibronectin and endogenous rat cell fibronectin in extracellular matrix. J Cell Biol 83, 255-259.
43. Harima A, Nakaseko C, Yokota A, Kitagawa M, Morimoto C, Harigaya K, and Saito Y (2008). Fibronectin promotes cell proliferation of human pre-B cell line via its interactions with VLA-4 and VLA-5. Hematology 13, 236-243.
44. Paulus W, Baur I, Beutler AS, and Reeves SA (1996). Diffuse brain invasion of glioma cells requires β1 integrins. Lab Invest 75, 819-826.
45. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, Montagna L, Piccoli P, Chilosi M, and Caligaris-Cappio F (2001). Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97, 2777-2783.
46. Sah NK, Khan Z, Khan GJ, and Bisen PS (2006). Structural, functional and therapeutic biology of survivin. Cancer Lett 244, 164-171.
47. Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K, Nakano T, Miura M, and Shiraki K (2000). Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 19, 1346-1353.
48. Black KL, Chen K, Becker DP, and Merrill JE (1992). Inflammatory leukocytes associated with increased immunosuppression by glioblastoma. J Neurosurg 77, 120-126.
49. Zhou J, Bi C, Janakakumara JV, Liu SC, Chng WJ, Tay KG, Poon LF, Xie Z, Palaniyandi S, Yu H, et al. (2009). Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood 113, 4052-4062.
50. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P, Sutmuller RP, and Adema GJ (2007). CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121, 95-105.